FTSE MIB
34.249,77 +310,02 (+0,91%) Dow Jones
38.239,66 +153,86 (+0,40%) Nasdaq
15.927,90 +316,14 (+2,03%) Nikkei 225
37.934,76 +306,28 (+0,81%) Petrolio
83,66 +0,09 (+0,11%) Bitcoin EUR
58.912,69 -605,03 (-1,02%)
QGEN Jun 2024 65.000 call
| Chiusura precedente | 0,2000 |
| Aperto | 0,2000 |
| Denaro | 0,0000 |
| Lettera | 0,0000 |
| Prezzo d'esercizio | 65,00 |
| Scadenza | 2024-06-21 |
| Min-Max giorno | 0,2000 - 0,2000 |
| Contratto - Min-Max | N/D |
| Volume | |
| Open Interest | 24 |
GlobeNewswireQIAGEN N.V. to release results for Q3 2023 and hold webcast
Venlo, the Netherlands, Oct. 09, 2023 (GLOBE NEWSWIRE) -- QIAGEN N.V. (NYSE: QGEN) (Frankfurt Stock Exchange: QIA) announced its plans to release results for the third quarter 2023. Press release date / time: Monday, October 30, shortly after 21:05 Frankfurt time / 20:05 London time / 16:05 New York time. (For Europe: Due to the U.S. time switch, our Press release will be published one hour earlier than usual.) Conference call date / time: Tuesday, October 31, at 14:00 Frankfurt time / 13:00 Lon
GlobeNewswireQIAGEN launches QuantiFERON-EBV RUO assay, facilitating research of cell-mediated immune response to Epstein-Barr virus
QuantiFERON-EBV RUO to help researchers understand Epstein-Barr virus (EBV) infections and related malignancies, offering a dynamic view of the host immune response // Advancing research in oncology and autoimmune diseases through measurement of T-cell responses to EBV, providing valuable insights into the virus’ role in these conditions // Further expanding portfolio of QuantiFERON cell-mediated immune response tests beyond tuberculosisVenlo, the Netherlands, Oct. 04, 2023 (GLOBE NEWSWIRE) -- Q
GlobeNewswireQIAGEN extends AI capabilities of its NGS interpretation software QCI Interpret to enable clinical exome completeness
AI-driven literature extraction for thousands of rare disease genes fortifies and extends QIAGEN’s proprietary, human-certified content, providing complete bibliographic coverage of the clinical exome // Enhanced AI-trained phenotype driven ranking of pathogenic variants improves accuracy and efficiency of prioritizing candidate variants // New features reduce time needed for prioritization, assessment and interpretation of clinically relevant variants and facilitate access to trusted evidence f
